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Summary
Background: There is increasing evidence supporting the relevance of aberrant splic-
ing in multiple disorders. In antithrombin deficiency only 22 intronic mutations affect-
ing splicing sites (7% of SERPINC1 mutations) are considered as splicing mutations.
Methods: SERPINC1 was analyzed by Sanger sequencing and MLPA in 141 unrelated 
cases with antithrombin deficiency. Plasma antithrombin was studied by functional 
and western blot assays, purified by FPLC and characterized by proteomic analysis. In 
silico predictions on splicing was done with the Human Splicing Finder software.
Results: We detected 89 different SERPINC1 defects, 13 with potential effect on splic-
ing. Ten cases presented 9 mutations disturbing splicing sites, 5 new. Three gross or 
small gene defects also disturbed a correct splicing. Interestingly, the first duplication 
of a single exon ever described (c.1154- 13_1218+115dup), caused mild deficiency 
(75%). A deeper intronic mutation (c.1154- 14G>A), identified in three unrelated pa-
tients with traces of disulphide dimers of antithrombin in plasma, created a cryptic 
splicing site that might generate a variant with 4 additional in frame residues according 
to in silico predictions. This aberrant splicing was confirmed by proteomic analysis of 
the dimer purified from plasma.
Conclusions: A high proportion of cases with antithrombin deficiency (up to 13%) may be 
explained by an aberrant splicing. Up to 15% of mutations in SERPINC1: splicing site varia-
tions, gross gene defects and deep intronic mutations, may affect a correct splicing with 
three potential consequences type I, type II, and even moderate antithrombin deficiency.
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Essentials
• Increasing evidence supports a role for splicing defects in multiple disorders.
• For antithrombin (AT) deficiency only 7% of mutations disturb intronic splicing sequences.
• Our study of 141 unrelated cases with AT deficiency found higher rate of splicing defects (>13%).
• A wide range of gene defects cause different types of AT deficiency through aberrant splicing.
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1  | INTRODUCTION
Antithrombin is a serpin (serin- protease inhibitor) considered as the 
main endogenous anticoagulant in humans. It exerts its anticoagulant 
function by inhibiting crucial serine proteases of the clotting cascade, 
mainly thrombin and factor Xa.1 Thus, inherited antithrombin defi-
ciency significantly increases the risk of thrombosis (20- to 40- fold). 
Congenital antithrombin deficiency is a heterogeneous disorder that 
shows an autosomal dominant pattern of inheritance. Deficiency is 
estimated to have a prevalence of about 0.02% in the general pop-
ulation, while accounting for 1% of cases with confirmed deep vein 
thrombosis.2 Two deficiency states are described: type I deficiency 
characterized by a parallel reduction in both functional and antigenic 
levels of antithrombin in plasma; and type II deficiency distinguished 
by the production and secretion of a variant protein to the plasma cir-
culation with null or impaired inhibitor activity.3
The gene encoding antithrombin, SERPINC1, is located on the long 
arm of chromosome 1 (q23- 25), and comprises 7 exons and 6 introns 
spanning 13 574 bp of genomic DNA (ENSG00000117601). Non- 
coding regions consist of 11 980 bp (88% from the whole gene).4,5
Up to 80% of cases with suspicion of inherited antithrombin defi-
ciency are caused by SERPINC1 gene defects6, although other gene de-
fects may also cause antithrombin deficiency.7 According to the Human 
Gene Mutation Database (HGMD), missense or nonsense mutations 
constitute more than 50% to the genetic defects identified in SERPINC1, 
followed by small deletions (19%), gross deletions, and small insertions 
(8.5% and 8.1%, respectively). Only 22 mutations affecting introns that 
might theoretically disrupt the natural mRNA processing have been de-
scribed (7% of mutations identified in SERPINC1), all associated with 
type I deficiency. As different evidences are supporting the increased 
role of splicing defects on different human genetic diseases8,9, the aim 
of this study was to identify new SERPINC1 genetic variations underlying 
antithrombin deficiency through an incorrect splicing in one of the larg-
est cohorts of unrelated patients with this strong thrombophilia.
2  | MATERIALS AND METHODS
2.1 | Patients
During the last 20 years, our center recruited 141 unrelated 
Caucasian cases from different hospitals with suspicion of antithrom-
bin deficiency (plasma anti- FXa activity <80% of a reference plasma 
generated with 100 healthy blood donors) presenting 89 different 
SERPINC1 gene defects.
The study was approved by the Ethics Committees of the Hospital 
General Universitario Reina Sofia in Murcia, Spain. All patients or their 
relatives, and controls (blood donors for the reference plasma) pro-
vided written informed consent.
2.2 | Blood collection
Blood samples were collected without venous stasis from an antecubi-
tal vein in citrate- anticoagulated tubes (109 mmol L−1) and processed 
within 24 hour after extraction. The tubes were centrifuged for 
15 minute at 2000 g at room temperature, and the separated plasma 
was aliquoted and stored at −70°C until analysis. Genomic DNA was 
purified by the salting out following Puregen Blood Core KitB (Qiagen, 
Madrid, Spain) procedure and stored at −20°C.
The first sample was obtained at least 6 months after the throm-
botic event, when the patient was not under any anticoagulant ther-
apy. No patient was evaluated under heparin treatment.
2.3 | Antithrombin evaluation
2.3.1 | Functional and antigenic assays
Antithrombin deficiency was identified by using different commer-
cial functional methods available in each hospital10, and confirmed 
in the sample delivered to our laboratory by evaluating plasma anti- 
FXa activity using a chromogenic method in the presence of heparin 
(HemosIL Liquid Antithrombin, Instrumentation Laboratory, Munich, 
Germany) in a plate reader (Synergy HT, Biotek).
Antigen levels were measured by immunodiffusion (Laurell) or 
home- made ELISA using rabbit polyclonal anti- human antithrombin 
(A9522, Sigma- Aldrich), mouse monoclonal anti- human antithrombin 
(A5816, Sigma- Aldrich) and anti- mouse ECL IgG horseradish peroxi-
dase (NA931 Amersham Biosciences, Piscataway, NJ, USA).
The normal range of antithrombin measurements (anti- FXa and 
antigen levels) was 80- 120% with coefficient of variation of 5- 7%.
2.3.2 | Western blot analysis
Plasma antithrombin was evaluated by Western blot using differ-
ent electrophoretic conditions described elsewhere.11 The blotting 
was performed by using rabbit anti- human antithrombin polyclonal 
antibody (A9522, Sigma- Aldrich) followed by donkey anti- rabbit 
IgG- horseradish peroxidase conjugate (NA9340, GE Healthcare, 
Barcelona, Spain) as secondary antibody.
Detection was carried out with an ECL kit (Amersham Biosciences, 
Piscataway, NJ, USA) in the ImageQuant LAS4000mini equipment 
(Exon Biotec, GE Healthcare).
2.3.3 | Protein purification
Antithrombin disulphide- linked dimers from plasma of patients with 
c.1154- 14G>A or the c.334C>T mutations were purified as described 
before.12 Briefly, citrated plasma of patients were subjected to heparin 
affinity chromatography on HiTrap Heparin columns (GE Healthcare), 
followed by ion exchange chromatography on HiTrap Q columns 
(GE Healthcare) and a gel filtration. All procedures were done in an 
ÄKTA Purifier (GE Healthcare). Finally, proteins eluted were desalted 
through a dialysis tubing (Sigma- Aldrich) and stored at −70°C, prior 
to analysis. After electrophoretic analysis (SDS- PAGE), bands corre-
sponding to dimers purified from patients with c.1154- 14G>A muta-
tion and wild type antithrombin, were subjected to in- gel digestion 
with 200 ng of sequencing grade modified Trypsin (Promega, Madrid, 
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Spain) in 50 mmol L−1 ammonium bicarbonate for 16 hour at 37°C, 
after a denaturation step with DTT (10 mmol L−1, 30 minute, 40°C) 
and an alkylation step with Iodoacetamide (25 mmol L−1, 30 minute, 
room temperature). The resulting peptides were extracted with 1% 
formic acid, 50% acetonitrile and evaporated to dryness prior to LC- 
MSMS analysis.
2.3.4 | LC−ESI−MS/MS analysis
Microcapillary reverse- phase LC was performed with a nanoAcquity 
system (Waters, Saint- Quentin, France). Reversed phase separa-
tion of trypsin digests was performed with an Atlantis, C18, 3 μm, 
75 μm×10 cm Nano Ease fused silica capillary column (Waters) buff-
ered in 5% acetonitrile with 0.2% formic acid. After injection of sam-
ple, the column was washed for 5 minute with the same buffer as 
above, and the peptides were eluted using a linear gradient of  5- 50% 
acetonitrile in 30 minute at a constant flow rate of 0.2 μL min−1. The 
column was coupled online with a Q- TOF Micro (Waters) using a 
PicoTipnanospray ionization source (Waters). The heated capillary 
temperature was 80°C and the spray voltage was 1.8- 2.2 kV. MS/
MS data were collected in an automated, data- dependent mode. 
The three most intense ions in each survey scan were sequentially 
fragmented by collision induced dissociation (CID) using an isolation 
width of 2.5 and a relative collision energy of 35%. Data processing 
was performed with MassLynx 4.0. Database searching was done 
with MASCOT Daemon v2.3.0 (MatrixScience, London, UK) against 
UniprotKB/Swiss- Prot database, and against an in- house database 
including Antithrombin sequence plus c.1154- 14G>A variant. Mass 
error tolerance was 50 ppm for parent and 0.1 Da for fragments; 
there were no restrictions on molecular weight and isoelectric point; 
the fixed modification was carbamidomethylation of cysteine; the 
variable modification was oxidation of methionine.
2.3.5 | Genetic analysis
The exons and flanking regions, as well as 1500 bp of the promoter 
region of SERPINC1, were sequenced in all patients with antithrom-
bin deficiency.13 Gross deletions were analyzed by multiplex ligation- 
dependent probe amplification (MLPA) using the SALSAMLPA Kit 
P227 SerpinC1 (MRC Holland, Amsterdam, The Netherlands).
2.3.6 | In silico analysis of potential splicing signals
To analyze the potential effect of mutations on sequences potentially 
involved in splicing, we used the Human Splicing Finder software 
(HSF, version 3.014). We consider potentially relevant those motifs 
TABLE  1 Demographic and clinical data of patients with antithrombin deficiency caused by a potential aberrant splicing
Patient
Age 
(years) Variant ID Mutation Pathogenicitya
Other risk 
factors Thrombosis
Anti- 
FXa 
(%)
Ag 
(%)
Type of 
AT 
deficiency
P1 45 CS013816 c.1218+1G>A Pathogenic DVT 50 60 I
P2 50 CS013816 c.1218+1 G>A Pathogenic DVT 29 42 I
P3 40 CS952107 c.1218+1G>T Pathogenic DVT 40 45 I
P4 29 CS011025 c.409- 1G>C Pathogenic CVT 52 51 I
P5 27 New c.863- 2A>C Pathogenic PE 55 50 I
P6 35 New c.1219- 3C>A Pathogenic FVL+/− PE 51 45 I
P7 21 New c.42- 2A>C Pathogenic Fatal PE 60 69 I
P8 31 CS132987 c.409- 2A>T Pathogenic AT Camb +/− PE 40 48 I
P9 40 New c.1154- 2A>T Pathogenic DVT 46 50 I
P10 15 New c.625- 2A>G Pathogenic 3 RecurrentDVT 58 52 I
P11 29 New c.1219- 1_1248del Pathogenic Mesenteric& portal 
thrombosis
47 50 I
P12 26 New Del exon 4 Pathogenic DVT 50 55 I
P13 42 New c.1154- 
13_1218+115dup
Pathogenic DVT 75 79 I moderate
P14 25 CS941423 c.1154- 14G>A Pathogenic PE 52 46 II
P15 56 CS941423 c.1154- 14G>A Pathogenic DVT 38 44 II
P16 32 CS941423 c.1154- 14G>A Pathogenic No 
(Severefamilyhistory)
39 47 II
P17 28 CM070261 c.470A>G 
p.[Lys157Arg]
Pathogenic FVL+/−& PT+/− DVT&PE 50 60 I
AG, Antigen levels; AT Cam, Antithrombin Cambridge II (p.Ala416Ser); CVT, Cerebral vein thrombosis; DVT, Deep venous thrombosis; FVL, Factor V 
Leiden; PE, Pulmonary embolism; PT, Prothrombin c.*97G>A; +/−, Heterozygous.
aPathogenicity according to American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines.29
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(acceptor or donor sites) that are disrupted or created as a conse-
quence of a specific variant with a score variation (difference between 
the reference wild type and mutant motif`s strengths) >20%, and in 
case of creating a new motif when it also reaches a score >80%.
3  | RESULTS
3.1 | Classical splicing mutations
Ten patients with severe thrombotic events (P1- P10) and type I an-
tithrombin deficiency (mean of 48% anti- FXa activity and 51% of 
antigen levels) had 9 different heterozygous splice site mutations 
(Table 1). Remarkably, P2 (with c.1218 +1G>A mutation) had lower 
antigen and anti- FXa activity than expected (Table 1), which may 
be explained by additional modulating factors. Five of these splicing 
site mutations were not previously described in available mutation 
databases (Table 1). All these mutations severely disturbed natural ac-
ceptor (N=7) or donor splicing sites (N=2). Three of them potentially 
affected the splicing of exon 6, two affecting exons 2 and 5, and single 
ones affecting the splicing of exons 1 and 3 (Table 1). It is remarkable 
that no mutation affecting the splicing of exon 4 has been described 
either in our cohort or in the HGMD.
3.2 | Other variants causing antithrombin deficiency 
through an aberrant splicing
3.2.1 | Small and gross gene defects
P11, a 29- year- old female with type I antithrombin deficiency (47% 
of anti- FXa activity and 50% of antigen levels) (Figure 1) who de-
veloped portal, mesenteric, and splenic vein thrombosis during 
pregnancy, had a new 31 bp deletion in heterozygosis (c.1219- 
1_1248del) affecting the last nucleotide of intron 6 and 30 bp of 
exon 7 (Table 1). According to HSF in silico predictions, this deletion 
disrupted the exon 7 wild type acceptor splicing site (from 90% to 
61% of splicing probability).
P12 and P13 (26- and 42- year- old patients with early deep venous 
thrombosis) presented gross gene rearrangements.
MLPA analysis of P12 revealed a profile suggesting a possi-
ble heterozygous deletion involving exon 4. Exon 4 must be ab-
sent from affected transcripts in P12. Accordingly, the processing 
of introns of the mutant transcript would be different from that 
followed by the wild type transcript, with altered reading frame 
resulting in a premature stop codon (Figure 2). This mechanism 
likely explains the type I antithrombin deficiency identified in P12 
(Table 1 and Figure 1).
F IGURE  1 Plasma antithrombin in P11, P12, and P13 patients 
detected by Western Blot after electrophoretic separation in native- 
PAGE. A healthy blood donor was used as a negative control. Anti- 
FXa activity and antigen levels are also indicated for each case.
P11 P12 P13 Control
47Anti-FXa (%)
Antigen (%)
50 75 100
100795550
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each exon
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In P13, PCR amplification and sequencing with primers flanking exon 6 
revealed an insertion of 193 bp covering exon 6 (c.1154- 13_1218+115dup) 
(Table 1). Surprisingly, P13 with duplication of exon 6, had a moderate type 
I deficiency of antithrombin with anti- FXa and antigen levels of around 
75% (Table 1 and Figure 1). The 193 bp duplication involving exon 6 may 
generate different potential alternative splicing, two of them able to ren-
der normal mRNA processing of SERPINC1, which may explain the moder-
ate antithrombin deficiency detected in this patient (Figure 2).
F IGURE  3  Identification and 
characterization of the c.1154- 14G>A 
mutation identified in three unrelated 
patients from our series (P14, P15 and 
P16). (A) Electropherogram showing the 
point mutation. (B) Electrophoretic analysis 
(SDS- PAGE) of plasma antithrombin under 
reducing and not- reducing conditions. 
Disulphide- linked dimers are highlighted by 
an arrow. As control of a missense mutation 
also generating disulphide- linked dimers, 
plasma from a patient with p.Pro112Ser 
mutation was also included. (C) Splicing 
predictions according to the results 
obtained with the Human Splicing Finder 
Software. (D) Purification of disulphide- 
linked dimers from plasma of patients with 
antithrombin deficiency heterozygous for 
c.1154- 14G>A and p.Pro112Ser mutations 
and proteomic analysis of the protein 
obtained from the patient with c.1154- 
14G>A mutation. N, nucleotides; aa, 
aminoacids.
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3.3 | Deep intronic mutations
Although the design of primers used in this study does not allow detect-
ing very deep intronic mutations, we identified one intronic variation 
not directly disturbing donor or acceptor sequences, c.1154- 14G>A, 
that might cause antithrombin deficiency. This mutation was detected 
in three unrelated patients from Portugal and two different regions of 
Spain: P14, P15 and P16 (Table 1). This mutation was previously de-
scribed in a Dutch patient with type I antithrombin deficiency, and au-
thors suggested this mutation to cause a splicing defect (CS941423).15 
Patients with this mutation from our cohort also showed an apparent 
type I deficiency, with a mean of around 50% of functional activity and 
antigen levels (Table 1). However, and in agreement with a previous 
report16 our patients with this mutation presented traces of disulphide- 
linked dimers in plasma, which had slightly slower electrophoretic mo-
bility than those identified in patients with conformational missense 
mutations (c.334C>T; p.Pro112Ser)11 (Figure 3).
In silico prediction suggested that c.1154- 14G>A creates a new 
cryptic acceptor sequence, which may potentially generate a vari-
ant protein with the in- frame insertion of 4 residues at position 384 
(Figure 3). Purification of disulphide- linked dimers from plasma of pa-
tients with this mutation and further proteomic analysis confirmed the 
predicted splicing in the variant protein (Figure 3).
4  | DISCUSSION
Point mutations are the most common cause of hereditary disease. Most 
of them (84% in the HGMD) have been considered to change a single 
aminoacid (missense) or generate a premature stop codon (nonsense).17,18 
However, in most cases mutation analyses are exclusively performed at 
the genomic DNA level, and the effect of a mutation on the encoded 
mRNA and protein is predicted from the primary sequence alone. Only few 
studies have evaluated experimentally the consequences of the mutation 
identified in a patient, and interestingly, about 50% of the mutations result 
in aberrant splicing.19,20 Actually, there is increasing evidence that many 
human disease genes are caused by mutations (also located at exons) that 
affect pre- mRNA splicing.8,9 Additionally, it is important to remark that the 
deleterious consequences of a mutation causing an aberrant splicing will 
potentially be higher than those from a missense mutation. Mutations af-
fecting splicing sites, donor or acceptor, have obvious consequences on 
splicing. However, also nonsense, missense, and even synonymous muta-
tions can inactivate genes by inducing the splicing machinery to skip the 
mutant exons. In fact, it has been estimated that 1.6% of disease- causing 
missense mutations can affect splicing, and recent predictions suggest that 
approximately 7% of exonic variants in the general population may dis-
rupt splicing, which includes cryptic splicing.21,22 Similarly, coding- region 
single- nucleotide polymorphisms might cause phenotypic variability by 
influencing splicing accuracy or efficiency. Finally, the relevance of deep 
intronic mutations in disease has not been established, as most studies are 
restricted to exons and flanking regions.
On SERPINC1 only 22 mutations (7% of the total mutations identi-
fied) are accepted to affect a correct splicing. Most of them affecting 
splicing sites and all described in section 2.1 with type I antithrom-
bin deficiency, in accordance to the severe consequences that these 
types of mutations have in this structurally and functionally sensitive 
serpin. The results obtained in our cohort of 141 unrelated and con-
secutive patients with antithrombin deficiency are consistent with 
available data from mutation databases: 10 cases with 9 different 
mutations affecting splicing sites, 5 of them new, all with type I de-
ficiency. These mutations represent 7% of our cohort and 10% of all 
different mutations identified in our study, which is similar to the rates 
described in other reports of large series.6,23 However, we also iden-
tified 4 additional gene defects in 6 patients with particular features 
and unexpected consequences that also caused antithrombin defi-
ciency by inducing an aberrant splicing. Thus, gross gene defects such 
as deletions or duplications of exons (the last one firstly described 
worldwide in SERPINC1) may cause antithrombin deficiency by signifi-
cantly affecting the correct splicing. Actually, the only way to explain 
the mild antithrombin deficiency observed in the patient with exon 
6 duplication (75% of anti- FXa activity and 79% of antigen levels) is 
by alternative splicing (Figure 2). Additionally, deep intronic mutations 
may also cause antithrombin deficiency. In this framework, we would 
like to point out the effect of the point mutation affecting intron 5, 
14 bp upstream exon 6. The cryptic acceptor splicing site generated 
by the nucleotide change G>A in intron 5 results in an altered mRNA 
with 12 bp added in frame that would code for 4 extra amino acids 
in the polypeptide chain.15 However, in contrast to original proposi-
tion that the mutant allele is not expressed at the protein level15 our 
study demonstrates that this variant is expressed and forms disulphide 
dimers by disturbing the correct folding of this serpin, like other mis-
sense mutations.11 This is the first evidence that an aberrant splicing 
may also cause a type II antithrombin deficiency.
In conclusion, our study shows new evidences supporting that splic-
ing mutations may play a more important role than previously thought 
in human hereditary disease. Aberrant splicing underlies a high propor-
tion of cases with antithrombin deficiency, at least twice than the num-
bers proposed nowadays. Our study also confirms that the distortion 
of the correct splicing might be the mechanism involved in antithrom-
bin deficiency caused by different types of gene defects. In addition 
to classical splicing site variations, deep intronic mutations and other 
gene variations including gross gene defects may cause antithrombin 
deficiency through an aberrant splicing. Missense and nonsense mu-
tations in SERPINC1 might also disturb a correct splicing, as suggested 
by a recent study.9 This large in silico study revealed that 21 out of 22 
nonsense and 2 missense SERPINC1 mutations described in databases 
have high probability to affect the splicing.9 Interestingly, one of these 
mutations, CM070261 p.(Lys157Arg) was identified in a patient from 
our cohort (P17) who had a type I deficiency (Table 1) despite this muta-
tion affects a residue involved in the binding of heparin.24 Therefore, it is 
possible that the number of mutations associated with aberrant splicing 
could be even higher than that suggested in this study, and it may in-
crease if considering other regulatory elements involved in the splicing 
process. However, it is important to point out the requirement of fur-
ther studies to verify the aberrant splicing suggested for mutations de-
scribed in SERPINC1, which may include recombinant models, analysis 
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of SERPINC1 transcripts and minigene models. Finally, our study shows 
that the consequences of an aberrant splicing are not restricted to the 
absence of protein encoded from the affected allele. As demonstrated 
in this study, an aberrant splicing in SERPINC1 may cause type I, type II 
or even moderate deficiency. As a final consideration; the elucidation 
of the pathological mechanism associated to one mutation is not only 
important from a basic point of view. It is also relevant for establishing 
the most appropriate and personalized therapeutic strategy at the mo-
lecular level, particularly with the promising results obtained to rescue 
mutations causing aberrant splicing.25–28
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